459 related articles for article (PubMed ID: 27595393)
1. On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models.
Cho H; Du X; Rizzi JP; Liberzon E; Chakraborty AA; Gao W; Carvo I; Signoretti S; Bruick RK; Josey JA; Wallace EM; Kaelin WG
Nature; 2016 Nov; 539(7627):107-111. PubMed ID: 27595393
[TBL] [Abstract][Full Text] [Related]
2. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
3. Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy.
Martínez-Sáez O; Gajate Borau P; Alonso-Gordoa T; Molina-Cerrillo J; Grande E
Crit Rev Oncol Hematol; 2017 Mar; 111():117-123. PubMed ID: 28259286
[TBL] [Abstract][Full Text] [Related]
4. HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.
Nicholson HE; Tariq Z; Housden BE; Jennings RB; Stransky LA; Perrimon N; Signoretti S; Kaelin WG
Sci Signal; 2019 Oct; 12(601):. PubMed ID: 31575731
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of
Stransky LA; Vigeant SM; Huang B; West D; Denize T; Walton E; Signoretti S; Kaelin WG
Proc Natl Acad Sci U S A; 2022 Apr; 119(14):e2120403119. PubMed ID: 35357972
[TBL] [Abstract][Full Text] [Related]
6. Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth.
Chen L; Xia G; Qiu F; Wu C; Denmon AP; Zi X
Sci Rep; 2016 Sep; 6():32582. PubMed ID: 27581364
[TBL] [Abstract][Full Text] [Related]
7. HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions.
Tella SH; Taïeb D; Pacak K
Eur J Cancer; 2017 Nov; 86():1-4. PubMed ID: 28946040
[TBL] [Abstract][Full Text] [Related]
8. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
Casagrande S; Ruf M; Rechsteiner M; Morra L; Brun-Schmid S; von Teichman A; Krek W; Schraml P; Moch H
J Pathol; 2013 Mar; 229(4):525-34. PubMed ID: 23007793
[TBL] [Abstract][Full Text] [Related]
9. 3-[(1
Xu R; Wang K; Rizzi JP; Huang H; Grina JA; Schlachter ST; Wang B; Wehn PM; Yang H; Dixon DD; Czerwinski RM; Du X; Ged EL; Han G; Tan H; Wong T; Xie S; Josey JA; Wallace EM
J Med Chem; 2019 Aug; 62(15):6876-6893. PubMed ID: 31282155
[TBL] [Abstract][Full Text] [Related]
10. SHARPIN regulates the development of clear cell renal cell carcinoma by promoting von Hippel-Lindau protein ubiquitination and degradation.
Yin R; Liu S
Cancer Sci; 2021 Oct; 112(10):4100-4111. PubMed ID: 34339558
[TBL] [Abstract][Full Text] [Related]
11. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
Petrella BL; Brinckerhoff CE
Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472
[TBL] [Abstract][Full Text] [Related]
12. ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma.
Green YS; Ferreira Dos Santos MC; Fuja DG; Reichert EC; Campos AR; Cowman SJ; Acuña Pilarte K; Kohan J; Tripp SR; Leibold EA; Sirohi D; Agarwal N; Liu X; Koh MY
Oncogene; 2022 Oct; 41(42):4709-4723. PubMed ID: 36097192
[TBL] [Abstract][Full Text] [Related]
13. Targeting HIF2α in Clear-Cell Renal Cell Carcinoma.
Ricketts CJ; Crooks DR; Linehan WM
Cancer Cell; 2016 Oct; 30(4):515-517. PubMed ID: 27728802
[TBL] [Abstract][Full Text] [Related]
14. Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385).
Wehn PM; Rizzi JP; Dixon DD; Grina JA; Schlachter ST; Wang B; Xu R; Yang H; Du X; Han G; Wang K; Cao Z; Cheng T; Czerwinski RM; Goggin BS; Huang H; Halfmann MM; Maddie MA; Morton EL; Olive SR; Tan H; Xie S; Wong T; Josey JA; Wallace EM
J Med Chem; 2018 Nov; 61(21):9691-9721. PubMed ID: 30289716
[TBL] [Abstract][Full Text] [Related]
15. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma.
Gong K; Zhang N; Zhang K; Na Y
Int J Mol Med; 2010 Dec; 26(6):907-12. PubMed ID: 21042786
[TBL] [Abstract][Full Text] [Related]
16. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.
Carew JS; Esquivel JA; Espitia CM; Schultes CM; Mülbaier M; Lewis JD; Janssen B; Giles FJ; Nawrocki ST
PLoS One; 2012; 7(1):e31120. PubMed ID: 22295124
[TBL] [Abstract][Full Text] [Related]
17. Gramicidin A blocks tumor growth and angiogenesis through inhibition of hypoxia-inducible factor in renal cell carcinoma.
David JM; Owens TA; Inge LJ; Bremner RM; Rajasekaran AK
Mol Cancer Ther; 2014 Apr; 13(4):788-99. PubMed ID: 24493697
[TBL] [Abstract][Full Text] [Related]
18. PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.
Yoshino H; Nohata N; Miyamoto K; Yonemori M; Sakaguchi T; Sugita S; Itesako T; Kofuji S; Nakagawa M; Dahiya R; Enokida H
Cancer Res; 2017 Nov; 77(22):6321-6329. PubMed ID: 28951458
[TBL] [Abstract][Full Text] [Related]
19. Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.
Fan Y; Li H; Ma X; Gao Y; Bao X; Du Q; Ma M; Liu K; Yao Y; Huang Q; Zhang Y; Zhang X
Oncotarget; 2016 Apr; 7(14):18280-94. PubMed ID: 26943772
[TBL] [Abstract][Full Text] [Related]
20. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
